These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38727613)

  • 1. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
    Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimony susceptible
    Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
    Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
    Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
    Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
    Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
    Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
    Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
    Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
    Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
    Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
    Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
    PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
    Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
    Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.